Our study presents a promising new approach for developing vaccines against amyloid diseases, such as PD and other synucleinopathies, by emphasizing the importance of the disease‐relevant pathological conformation of the target, here alpha‐synuclein fibrils. Here, SNCA is linked to synucleinopathy.